NO20014560L - Quinasoliner og terapautisk anvendelse derav - Google Patents

Quinasoliner og terapautisk anvendelse derav

Info

Publication number
NO20014560L
NO20014560L NO20014560A NO20014560A NO20014560L NO 20014560 L NO20014560 L NO 20014560L NO 20014560 A NO20014560 A NO 20014560A NO 20014560 A NO20014560 A NO 20014560A NO 20014560 L NO20014560 L NO 20014560L
Authority
NO
Norway
Prior art keywords
quinasolines
therapeutic use
treatment
cancer
methods
Prior art date
Application number
NO20014560A
Other languages
English (en)
Other versions
NO20014560D0 (no
Inventor
Fatih M Uckun
Xing-Ping Liu
Rama K Narla
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Publication of NO20014560L publication Critical patent/NO20014560L/no
Publication of NO20014560D0 publication Critical patent/NO20014560D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Quinazolinforbindelser og fremgangsmåter for behandlingen av kreft og for behandlingen av allergiske reaksjoner.
NO20014560A 1999-03-19 2001-09-19 Quinasoliner og terapautisk anvendelse derav NO20014560D0 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12517799P 1999-03-19 1999-03-19
US12533899P 1999-03-19 1999-03-19
US12514599P 1999-03-19 1999-03-19
US09/357,404 US6258820B1 (en) 1999-03-19 1999-07-20 Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
PCT/US2000/006902 WO2000056720A1 (en) 1999-03-19 2000-03-16 Quinazolines and therapeutic use thereof

Publications (2)

Publication Number Publication Date
NO20014560L true NO20014560L (no) 2001-09-19
NO20014560D0 NO20014560D0 (no) 2001-09-19

Family

ID=27494574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014560A NO20014560D0 (no) 1999-03-19 2001-09-19 Quinasoliner og terapautisk anvendelse derav

Country Status (10)

Country Link
US (5) US6258820B1 (no)
EP (1) EP1163228A1 (no)
JP (1) JP2002540103A (no)
KR (1) KR20020011973A (no)
AU (1) AU4171900A (no)
CA (1) CA2367861A1 (no)
IL (1) IL144954A0 (no)
MX (1) MXPA01009453A (no)
NO (1) NO20014560D0 (no)
WO (1) WO2000056720A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
WO2001036394A1 (en) * 1999-11-15 2001-05-25 Parker Hughes Institute 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
US6482828B1 (en) 1999-11-15 2002-11-19 Parker Hughes Institute 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
CA2414406A1 (en) * 2000-06-26 2002-01-03 The Regents Of The University Of Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
ATE412657T1 (de) * 2002-12-24 2008-11-15 Astrazeneca Ab Therapeutische quinazolin-derivate
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
CA2557433C (en) * 2004-02-19 2013-05-14 Rexahn Corporation Quinazoline derivatives and therapeutic use thereof
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
CN101362719B (zh) * 2007-08-06 2012-04-18 北京师范大学 喹啉类衍生物以及包含其的组合物
AU2008319366B2 (en) * 2007-10-29 2012-03-01 Amgen Inc. Benzomorpholine derivatives and methods of use
BRPI0819453A2 (pt) 2007-11-28 2014-10-07 Dana Farber Cancer Inst Inc Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
MX2010012442A (es) 2008-05-13 2011-10-11 Astrazeneca Ab Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina.
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101659658B (zh) * 2008-08-29 2014-04-02 北大方正集团有限公司 氰基取代的喹啉衍生物
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2752413B1 (en) 2012-03-26 2016-03-23 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Quinazoline derivative and application thereof
US10646465B2 (en) 2015-12-17 2020-05-12 Biokine Therapeutics Ltd. Small molecules against cancer
US11129824B2 (en) 2015-12-17 2021-09-28 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
JP7370079B2 (ja) * 2018-06-06 2023-10-27 国立大学法人北海道大学 グリオーマの処置剤および医薬組成物
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
CA3107453A1 (en) * 2018-07-23 2020-01-30 Ohio State Innovation Foundation Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
CA3090315C (en) 2019-05-15 2023-09-19 Biokine Therapeutics Ltd. 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
US20230390277A1 (en) * 2020-10-21 2023-12-07 Ohio State Innovation Foundation Methods to sensitize tumors to treatment by immunotherapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507052A (ja) 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
AU4171900A (en) 2000-10-09
MXPA01009453A (es) 2002-05-14
JP2002540103A (ja) 2002-11-26
EP1163228A1 (en) 2001-12-19
US7038049B2 (en) 2006-05-02
US20050075353A1 (en) 2005-04-07
US6258820B1 (en) 2001-07-10
US6638939B2 (en) 2003-10-28
US6358962B2 (en) 2002-03-19
US20020137757A1 (en) 2002-09-26
WO2000056720A1 (en) 2000-09-28
CA2367861A1 (en) 2000-09-28
IL144954A0 (en) 2002-06-30
NO20014560D0 (no) 2001-09-19
KR20020011973A (ko) 2002-02-09
US20010016588A1 (en) 2001-08-23
US20040039002A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
EE200200673A (et) Kinasoliini derivaadid kasvajate raviks
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
NO20034780D0 (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
NO20024610L (no) Synergistiske metoder og blandinger for behandling av kreft
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
NO20033883D0 (no) Heterosykliske derivater for behandling av kreft og andre proliferative sykdommer
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
PT1235571E (pt) Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
IL161059A0 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
NO20020358D0 (no) Anvendelse av etodolac for behandling av kreft
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
NO20020784L (no) Medikament for behandling av brudd
NO20033341D0 (no) Metoder for administrering av epothilone-analoger for behandling av kreft

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application